Edwin Madison
First SEC filing: Dec. 15, 2015 · Latest: Dec. 15, 2015
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Oct. 22, 2015 | GYRE | A | 58,572 | · | · | 58,572 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 22, 2015 | GYRE | A | 58,572 | · | · | 58,572 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 22, 2015 | GYRE | A | 71,428 | · | · | 71,428 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2015 | GYRE | J | 29 | · | · | 29 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2015 | GYRE | J | 11,254 | · | · | 11,254 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2015 | GYRE | J | 6,501 | · | · | 6,501 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2015 | GYRE | J | 26,809 | · | · | 26,809 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2015 | GYRE | J | 3,820 | · | · | 3,820 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2015 | GYRE | J | 31,008 | · | · | 31,008 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | Oct. 22, 2025 | 58,572 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | Oct. 22, 2025 | 58,572 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | Oct. 22, 2025 | 71,428 | Acquired |
| Aug. 20, 2015 | GYRE | Warrant (Right to Buy) | Common Stock | $33.27 | April 9, 2019 | 29 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $11.52 | Jan. 2, 2023 | 11,254 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $10.48 | Feb. 5, 2020 | 6,501 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $7.33 | March 16, 2019 | 26,809 | Acquired |
| Aug. 20, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $9.43 | April 9, 2018 | 3,820 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2016 | $279,415 | · | · | · | · | · | $405,452 | $695,833 |
| 2015 | $333,333 | $94,325 | · | · | · | · | · | $1,429,968 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.